Aesthetic manufacturer Teoxane presented a new injection technique for skin quality at the International Master Course on Ageing Science (IMCAS) Paris 2026.
Two scientific posters and a dedicated symposium detailed the Teoxane babyGLOW technique, a standardised, anatomy-based subdermal injection approach designed to support consistent product distribution while avoiding facial danger zones.
The company explains that the method involves Teosyal Puresense Redensity 1, a non-crosslinked hyaluronic acid formulation with a dermostructuring complex, selected for its high fluidity and suitability for dermal and subdermal skin redensification.
Mounia Heddad-Masson, director of global medical education and medical affairs at Teoxane, commented, “At IMCAS our ambition is to bring our educational standards, clinical rigor and scientific vision directly to the heart of the global aesthetic community. Teoxane babyGLOW is a clear expression of this approach. The technique was developed in close collaboration with a board of more than 20 expert injectors across six countries and refined through real-world clinical practice.”